- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02500732
Prevention of Syncope Trial 6 - Atomoxetine in Vasovagal Syncope (POST6)
A Proof of Principle Study of Atomoxetine for the Prevention of Vasovagal Syncope (VVS): POST6
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Background: Syncope affects about 50% of Canadians, is the cause of 1-2% of emergency room visits, and probably is responsible for C$250 million (Canadian dollars) in health care spending each year. It is associated with decreased quality of life, trauma, loss of employment, and limitations in daily activities. The most common cause is vasovagal syncope. This occurs in people of all ages, and is a lifelong predilection. While the median number of faints in the population is 2, those who come to the investigators' care have a median 10-15 lifetime spells, and have an increased frequency in the year before presentation. Vasovagal syncope is due to abrupt hypotension and transient bradycardia, which cause cerebral hypoperfusion. The pathophysiology may be either failure of venous return or progressive vasodilation, both due to inappropriately low sympathetic outflow.
There is no known medical treatment for frequent fainting. The investigators performed the pivotal Canadian Institutes of Health Research (CIHR)-funded randomized trials that showed that neither permanent pacing, beta blockers, nor fludrocortisone help the majority of patients. However 2 randomized studies suggest that inhibition of norepinephrine transport (NET) reuptake with sibutramine and reboxetine (NET inhibitors) prevents syncope on tilt testing by about 80%, and the investigators reported that sibutramine markedly reduced the frequency of vasovagal syncope in 7 of our most symptomatic patients. Sibutramine and reboxetine, for different reasons, are not available in Canada. However atomoxetine is available and is used to help patients with attention deficit disorder. There are no data pertaining to its hemodynamic effects in patients with vasovagal syncope. Although a randomized clinical trial of atomoxetine for the prevention of vasovagal syncope would be needed before clinical use, a proof of principle study is needed first.
Objective: To determine if atomoxetine 40 mg bid (bis in die) in patients ≥18 years old with recurrent vasovagal syncope will better prevent syncope during tilt testing than placebo.
Methods: The investigators will conduct a prospective, randomized, parallel, double-blind, proof-of-concept study to test the hypothesis that norepinephrine transporter inhibition with Atomoxetine prevents tilt-induced vasovagal syncope (VVS)/pre-syncope in patients with clinical vasovagal syncope. Subjects will have had ≥1 faint in the previous year, and a diagnosis of vasovagal syncope based on the Calgary Syncope Symptom Score. The primary outcome measure will be the time to syncope or presyncope with a trough rate-pressure product <7000 mm Hg/min. The primary analysis will be performed on an intention-to-treat basis. Secondary analyses will include modelled estimations of systemic vascular resistance and stroke volume, based on arterial waveform and blood pressure. This will permit us to address whether NET inhibition prevents the vasovagal reflex by maintenance of cardiac preload or maintenance of systemic vascular resistance. The investigators will randomize 64 patients in a double blind acute phase 2 study to either Atomoxetine 40mg PO bid x 2 doses or matching placebo.
A sample size of 56 syncope patients would have 85% power to detect a 60% relative risk reduction from a placebo outcome rate of 65%, using an unmatched 2-tailed test with alpha=0.05. To compensate for the report dropout rate we will inflate the sample by 15% to 64 subjects. A formal, blinded mid-way safety and efficacy analysis will be performed with a p<0.01 stopping rule for efficacy. The sample size will be inflated to 74 to account for spending power on the interim analysis. This will provide 85% power to detect an 80% relative risk reduction.
Relevance: This will be the first adequately powered study of the ability of atomoxetine to prevent the vasovagal reflex. It will also provide insight as to whether norepinephrine transport inhibition functions here to maintain venous return or increase systemic vascular resistance. If positive, the study will provide a strong biomedical rationale and preliminary clinical results leading to a randomized clinical trial of atomoxetine for the prevention of vasovagal syncope.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Alberta
-
Calgary, Alberta, Canada, T2N 4Z6
- University of Calgary
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 1 or more syncopal spells in the year preceding enrolment
- More than -2 points on the Calgary Syncope Symptom Score
- Age ≥18 years with informed consent
Exclusion Criteria:
- Other causes of syncope, such as ventricular tachycardia, complete heart block, orthostatic hypotension or hypersensitive carotid sinus syndrome
- Inability to give informed consent
- important valvular, coronary, myocardial or conduction abnormality or significant arrhythmia.
- hypertrophic cardiomyopathy
- a permanent pacemaker
- a seizure disorder
- hypertension defined as >150/90 mm Hg
- pregnancy
- glaucoma
- medications with known effects on blood pressure
- Known hypersensitivity to atomoxetine and derivatives
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
Placebo capsule to be given the night before the study tilt, and the morning of the study tilt test.
|
oral placebo capsule designed to blind the atomoxetine intervention
|
Active Comparator: Atomoxetine
Atomoxetine 40mg PO to be given the night before the study tilt, and the morning of the study tilt test.
|
40mg PO the night before and the morning of the study tilt table test.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of Participants Who Become Syncopal Associated With Diagnostic Criteria of Hypotension and Bradycardia
Time Frame: 1 hour post start of head up tilt
|
1 hour post start of head up tilt
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of Participants Who Become Presyncopal (Isolated) Associated With Diagnostic Criteria of Hypotension and Bradycardia
Time Frame: 1 hour post start of head up tilt
|
1 hour post start of head up tilt
|
Estimated Stroke Volume Index (From the Continuous BP Monitor) During Presyncope
Time Frame: From baseline to within 1 hour post start of head up tilt
|
From baseline to within 1 hour post start of head up tilt
|
Cardiac Index (From the Continuous BP Monitor) During Presyncope
Time Frame: From baseline to within 1 hour post start of head up tilt
|
From baseline to within 1 hour post start of head up tilt
|
Systematic Vascular Resistance Index (From the Continuous BP Monitor) During Presyncope
Time Frame: From baseline to within 1 hour post start of head up tilt
|
From baseline to within 1 hour post start of head up tilt
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Satish R Raj, MD MSCI, University of Calgary
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Nervous System Diseases
- Neurologic Manifestations
- Neurobehavioral Manifestations
- Autonomic Nervous System Diseases
- Unconsciousness
- Consciousness Disorders
- Primary Dysautonomias
- Orthostatic Intolerance
- Syncope
- Syncope, Vasovagal
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Adrenergic Uptake Inhibitors
- Atomoxetine Hydrochloride
Other Study ID Numbers
- POST6
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Vasovagal Syncope
-
University of CalgaryNot yet recruitingSyncope | Vasovagal Syncope (VVS)Canada
-
David B. De LurgioBiosense Webster, Inc.CompletedNeurocardiogenic Syncope | Vasovagal SyncopeUnited States
-
Hospices Civils de LyonNot yet recruiting
-
University of CalgaryRecruiting
-
Dr. Bob SheldonVanderbilt UniversityActive, not recruitingVasovagal SyncopeUnited States, Canada, Poland
-
University of CalgaryVanderbilt UniversityActive, not recruitingVasovagal SyncopeCanada
-
Aarhus University Hospital SkejbyAarhus University Hospital; Biotronik SE & Co. KGCompleted
-
University of CalgaryCanadian Institutes of Health Research (CIHR)CompletedSyncope, Vasovagal, Neurally-MediatedUnited States, Canada
-
Azienda Ospedaliera Cardinale G. PanicoCompletedSyncope, Vasovagal, Neurally-MediatedItaly
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States